Examination of the effect of continuous intake of Lactic acid bacteria on immune function and health condition maintenance.
- Conditions
- Healthy adults
- Registration Number
- JPRN-UMIN000042485
- Lead Sponsor
- IMEQRD Co., Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 59
Not provided
1.Those who are currently receiving any types of medicines and/or Chinese medical treatment (except for the drugs taken as needed) 2.Those who are on diet and exercise therapy under the supervision of a doctor 3. Those who have or had a severe disease 4.Persons with atopic dermatitis, allergic rhinitis (perennial / seasonal), bronchial asthma, chronic bronchitis 5.Those who are currently using quasi-drugs, foods for specified health use, health foods and supplements and cannot stop during the test period after obtaining consent 6.Those who regularly use foods containing lactic acid bacteria and bifidobacteria 7.Those who have been vaccinated with influenza vaccine after October 2020, or those who are planning to be vaccinated during the test period 8.Those who have a current or previous history of drug and/or food allergies 9.Those who work in shifts, or night shifts 10.Those who plan to travel abroad, such as traveling abroad, during the test period 11.Those who are currently pregnant or breastfeeding or those who want to become pregnant during the test period 12.Those who have participated in or are currently participating in other clinical trials within one month before obtaining consent, or those who are planning to participate during the trial period 13.Those who consume alcohol excessively (alcohol equivalent 60g or more / day) 14.Those who have excessive smoking habits (21 or more cigarettes / day) 15.Those who habitually engage in strenuous exercise such as marathons 16.Those who have bleeding teeth or oral problems (stomatitis, etc.) 17.Those who are judged to be unsuitable as subjects from the subject background survey. 18.Those who were determined by the investigator to be unsuitable for participation in this clinical trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Health condition questionnaire
- Secondary Outcome Measures
Name Time Method K activity, IFN-gamma, IL-12, pDC activity, saliva s-IgA